Evidence map›Paper›PMID 30291251›Full record

ReviewNature reviews. Disease primers2018

Testicular cancer.

Liang Cheng, Peter Albers, Daniel M Berney, Darren R Feldman, Gedske Daugaard, Timothy Gilligan, Leendert H J Looijenga

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 260 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  11. Trial
  12. Article
  13. Case - Ovarian-type cancer in males: Paratesticular serous papillary carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. The Need to Know in Cardio-Oncology.JACC. Case reports · 2026
    Article
  18. Article
  19. Article
  20. Article

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liang ChengDepartments of Pathology and Laboratory Medicine and Urology, Indiana University School of Medicine, Indianapolis, IN, USA. lcheng@iupui.edu.
Peter AlbersDepartment of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany.
Daniel M BerneyDepartment of Molecular Oncology, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, UK.
Darren R FeldmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gedske DaugaardDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Timothy GilliganDepartment of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Leendert H J LooijengaDepartment of Pathology, Josephine Nefkens Building, Erasmus MC-University Medical Center, Cancer Institute, Rotterdam, Netherlands.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
6 · The paper itself

Abstract

Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

Indexed as

AdolescentAdultChromosome DisordersChromosomes, Human, Pair 12HumansIncidenceMaleQuality of LifeRisk FactorsTesticular Neoplasms

Identifiers

PMID30291251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.